Skip to main content

Table 2 Effect of policosanol, atorvastatin, and silymarin treatments on AST, ALT, and ALP in the HFD-fed animals

From: Therapeutic potential of policosanol in the concurrent management of dyslipidemia and non-alcoholic fatty liver disease

Serum parameters

Normal control

Disease control (HFD)

Policosanol 50 (mg/kg) + HFD

Policosanol 100 (mg/kg) + HFD

Atorvastatin30 (mg/kg) + HFD

Silymarin 100 (mg/kg) + HFD

AST (IU/L)

45.45 ± 6.10

89.46 ± 9.89@@@

74.32 ± 9.01

52.56 ± 7.29***

59.84 ± 6.54***

56.18 ± 5.98***

ALT (IU/L)

41.52 ± 5.69

78.14 ± 9.09@@@

70.65 ± 6.92

60.83 ± 12.18**

52.42 ± 6.77***

50.64 ± 5.46***

ALP (IU/L)

98.48 ± 15.64

167.51 ± 22.43@@@

150.83 ± 19.88

134.81 ± 13.13*

120.12 ± 13.89***

125.56 ± 16.92**

BILIRUBIN (IU/L)

0.76 ± 0.18

1.77 ± 0.31@@@

1.39 ± 0.33

0.101 ± 0.27***

1.19 ± 0.11**

0.91 ± 0.18***

  1. Data are represented as mean ± SD (n = 6)
  2. @@@p < 0.001 compared with the normal control group
  3. *p < 0.05 compared with the HFD group
  4. **p < 0.01 compared with the HFD group
  5. ***p < 0.001 compared with the HFD group